Company news

Illumina, Inc. news in 2023

Illumina, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Illumina Announces Decision to Divest GRAIL

December 16, 2023

Illumina submits Form 10 to the Securities and Exchange Commission

December 10, 2023

Illumina launches Global Health Access Initiative to support acceleration of pathogen sequencing in low- and middle-income countries

November 12, 2023

Illumina Reports Financial Results for Third Quarter of Fiscal Year 2023

November 8, 2023

Illumina launches advanced liquid biopsy assay to enable comprehensive genomic profiling of solid tumors

October 31, 2023

Illumina responds to European Commission's divestiture order

October 12, 2023

Illumina to Announce Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 4, 2023

Illumina's Board Appoints Jacob Thaysen, Ph.D. as its New Chief Executive Officer

September 4, 2023

Illumina expands genomics capabilities in India with opening of Solutions Center

August 16, 2023

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2023

August 8, 2023

Dr. Steven Barnard Appointed Chief Technology Officer

August 8, 2023

Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research

July 31, 2023

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

July 24, 2023

Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

July 17, 2023

Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery

July 10, 2023

Illumina Ventures to Launch Illumina® Ventures Labs

June 19, 2023

Illumina announces CEO transition plan

June 10, 2023

Illumina releases 2022 Corporate Social Responsibility Report

June 4, 2023

Illumina's Board of Directors elects two experienced Independent Directors to Board

June 1, 2023

Illumina unveils AI software to predict disease-causing genetic mutations in patients

May 31, 2023

Illumina to Host Third Annual Virtual ESG Investor Event on Monday, June 12, 2023

May 30, 2023

Illumina announces preliminary results of annual meeting

May 24, 2023

Illumina Board Chair issues letter to shareholders and urges shareholders to vote the WHITE proxy card FOR all nine of Illumina's nominees

May 17, 2023

Illumina's genomic technologies enable better pathogen preparedness and response

May 15, 2023

Illumina sends letter to shareholders detailing why Illumina's nominees far outmatch Icahn's slate in skills and experience

May 14, 2023

Leading Proxy Advisory Firm ISS Recommends Illumina Shareholders Vote "FOR" Eight of Illumina's Highly Qualified Director Nominees

May 11, 2023

Illumina Sends Letter to Shareholders Highlighting Board Strength, Weakness of Icahn's "Plan"

May 7, 2023

Illumina increases equitable access to STEM education, reaching over 1 million learners

May 1, 2023

Illumina Issues Shareholder Letter and Requests Shareholders Vote for the Illumina Director Nominees on the WHITE Proxy Card

April 30, 2023

Illumina Reports Financial Results for First Quarter of Fiscal Year 2023; Announces Commitment to Accelerate Margin Growth

April 24, 2023

Illumina Urges Shareholders to Vote the WHITE Proxy Card FOR all Nine of Illumina's Nominees

April 19, 2023

Illumina's cloud-based informatics programs recognized for robust, international data privacy protections

April 11, 2023

Illumina and Henry Ford Health team up to study impact of comprehensive genomic testing for cardiovascular patients

April 10, 2023

Illumina celebrates 25 years of innovation

April 4, 2023

Illumina to Announce First Quarter 2023 Financial Results on Tuesday, April 25, 2023

April 3, 2023

Illumina's revolutionary NovaSeq X exceeds 200th order milestone in first quarter 2023

April 3, 2023

Illumina Will Appeal FTC Decision in Federal Court, Will Seek US Resolution by Late 2023 or Early 2024

April 2, 2023

Illumina Files Preliminary Proxy, Urging Shareholders to Vote for Its Director Nominees and Withhold for Each Icahn Group Nominee

March 29, 2023

Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

March 26, 2023

Illumina Issues Statement in Response to Carl Icahn's Letter

March 23, 2023

Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements

March 19, 2023

Illumina launches its first product enabling long- and short-read sequencing on one instrument

March 13, 2023

Illumina Responds to Icahn Partners' Nomination of Directors

March 12, 2023

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

March 1, 2023

Illumina delivers first NovaSeq X Plus sequencer to the Broad Institute

February 7, 2023

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2022

February 6, 2023

Illumina Appoints Joydeep Goswami Chief Financial Officer

January 31, 2023

Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 9, 2023

Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen

January 8, 2023

Calls in 2023

Decks in 2023